Wegovy belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, and its injected under the skin once weekly
The objective of such surveillance is to detect early metabolic drift toward constraint-sensitive states that could compromise long-term therapeutic durability
Large self-funded employers have increasingly been adding GLP-1 coverage as employee demand grows, but many smaller employers and fully insured groups have not, primarily because the cost impact on premiums is significant
Download Our Brochure on Metabolic Disease Models Explore Biocytogens Models for Obesity and Diabetes Drug Development Literature Reference: Prado, Carla M., et al
A., Llugany, M., Snchez-Martn, M.-J., Daurelio, L
Of these 14 RYBELSUS-treated patients, 7 patients (0.2% of the total RYBELSUS-treated study population) developed antibodies that cross-reacted with native GLP-1